Here at Abacus Medicine Pharma Services (AMPS) – the pharmaceutical services division of the Abacus Medicine Group – we’re driven by our purpose statement: Better Access ∙ Better Healthcare.
Abacus Medicine Group was founded in 2004 by CEO Flemming Wagner and his father John Wagner (1932-2018). Their vision was to support better healthcare for patients throughout Europe by improving access to original prescription medicines.
The Group has enjoyed rapid growth. It now employs over 1,200 people across nine locations, has over 8,000 marketing authorizations (MAs) and distributes over 22 million units/year.
A new generation of pharma services
We’re proud of the specialist role AMPS plays within the Group. We’ve built a leadership and management team with vast experience across the pharma and pharma services sectors. This, combined with the market-leading sourcing and analytical capabilities of the Abacus Medicine Group, puts us in an excellent position to support the existing and future pharma and biotechnology industries.
AMPS provides four key services that supports clients across the entire pharmaceutical product life cycle, as described below:
Innovative comparator sourcing and commercial distribution services
- Clinical Trial Solutions
Our Clinical Trial Solutions unit provides bespoke comparator sourcing to support the efficient running of clinical trials for biosimilar, biotechnology, and other innovative pharmaceutical companies.
We support all stages of clinical development, from pre-clinical to Phases I, II and III trials. Via the Abacus Medicine Group, we have continuous access to more than 8,000 key brands across multiple markets, as well as sophisticated market analysis tools. This gives us an unrivalled inventory and supplier network. These unique capabilities allow us to provide a wide range of innovative hybrid sourcing solutions for our partners.
- Commercial Partnerships
Our Commercial Partnerships service supports pharma companies by providing an integrated end-to-end approach to help bring licensed products to European markets. We develop market access solutions that provide patients with the fastest access to new treatments. We implement high-impact commercial strategies to capture critical value-creation opportunities.
We provide a high-touch speciality distribution service for pharmaceutical products, delivering them directly to healthcare establishments in a timely and compliant manner. We also offer ancillary services such as labelling and packaging.
Here at AMPS, our broad knowledge and experience across the pharmaceutical industry, combined with our unique capabilities, allows us to create innovative and bespoke solutions that meet the needs of our partners, physicians and of course patients. We have special expertise in products for the treatment of rare and orphan diseases.
- Managed Access Program
Our Managed Access Program service supports products and companies in the late stages of development. The service provides a framework for a partnership in which AMPS creates, implements and manages a program on behalf of a pharmaceutical manufacturer to provide access to their product(s) in countries where it is not commercially available. This can be in the pre-launch or post-launch stage of the product life cycle. Each program is bespoke to the manufacturer’s unique needs.
- Unlicensed Medicines
Patients with unmet medical needs often require access to medicines that are not commercially available in their home countries. Our Unlicensed Medicines service enables this by gaining access to products that are not licensed locally but are licensed in other markets. When we receive such a request from a healthcare professional, if we do not already have the product in stock, we source the medicine and deliver it, in compliance with appropriate regulations, to the relevant medical establishment ready for the patient to receive treatment.